

STROKE DIAGNOSTICS AND THERAPEUTICS: GLOBAL MARKETS



HLC180A
March 2015

Bhavna Joshi
Project Analyst

ISBN: 1-62296-051-3



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY AND OBJECTIVE	2
STUDY BACKGROUND	2
SCOPE OF THE REPORT	3
INTENDED AUDIENCE	3
SOURCE OF INFORMATION AND METHODOLOGY	4
ANALYST'S CREDENTIALS	4
RELATED BCC RESEARCH REPORTS	5
BCC RESEARCH WEBSITE	5
DISCLAIMER	5
CHAPTER 2 EXECUTIVE SUMMARY	7
<i>SUMMARY TABLE GLOBAL STROKE MANAGEMENT MARKET, THROUGH 2019 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL STROKE MANAGEMENT MARKET, 2013-2019 (\$ MILLIONS)</i>	7
CHAPTER 3 MARKET OVERVIEW	11
STROKE AND CLASSIFICATION OF STROKE	11
ISCHEMIC	11
HEMORRHAGIC	13
INCIDENCE AND PREVALENCE RATES	13
<i>FIGURE 1 TOP 10 LEADING CAUSES OF DEATH IN THE WORLD, 2012 (MILLIONS)</i>	13
<i>TABLE 1 RISK FACTORS OF STROKE</i>	14
<i>FIGURE 2 NUMBER OF STROKES IN THE WORLD, 1990-2010 (MILLIONS)</i>	15
<i>FIGURE 3 GLOBAL INCIDENCE AND PREVALENCE OF STROKE BY REGION, 2010 (%)</i>	16
<i>TABLE 2 PREVALENCE OF STROKE IN THE U.K. BY REGION AND GENDER, 2010 (%)</i>	17
<i>TABLE 3 TOTAL NUMBER OF DEATHS FROM STROKE IN THE U.K. BY REGION, 2010 (NUMBER)</i>	18
<i>FIGURE 4 U.S. PREVALENCE OF STROKE BY AGE AND GENDER IN PERCENTAGE OF POPULATION, 2010 (%)</i>	18
CLINICAL DIAGNOSIS OF STROKE	19
<i>FIGURE 5 ALGORITHM FOR THE DIAGNOSIS OF ACUTE STROKE</i>	19
COMPUTED TOMOGRAPHY	20
MAGNETIC RESONANCE IMAGING (MRI)	20
CAROTID ULTRASOUND	20
CAROTID ANGIOGRAPHY	20
ELECTROCARDIOGRAM	21
ECHOCARDIOGRAPHY	21
BLOOD TESTS	21
THERAPEUTIC INTERVENTION	21
CAROTID ENDARTERECTOMY	21
THROMBOLYSIS	23
TECHNOLOGY DEVELOPMENTS - ROLE OF BIOMARKERS, RISK PREDICTION AND DIAGNOSIS	23
DISCOVERING BIOMARKERS FOR STROKE	23

TOPIC	PAGE NO.
APPLICATIONS OF BIOMARKERS IN STROKE RESEARCH	24
<i>TABLE 4 ROLE OF BIOMARKERS</i>	25
High-risk Subjects	26
Stroke Prediction	26
Possible Stroke Mechanisms	26
Drug Response and Outcome	26
Surrogate Endpoints	27
TYPE OF BIOMARKERS IN STROKE RESEARCH	27
<i>TABLE 5 BIOMARKERS FOR SPECIFIC STROKE SUBTYPES</i>	27
Protein Biomarkers	28
Genetic biomarkers	29
Microvesicle	29
Metabolomics	29
LIMITATIONS OF STROKE BIOMARKERS	29
<i>TABLE 6 ADVANTAGES AND DISADVANTAGES OF BIOMARKERS BY TYPE</i>	30
<i>TABLE 7 POST STROKE DISEASE MANAGEMENT - CLINICAL TRIAL</i>	30
<i>TABLE 8 CLINICAL TRIAL: A SELF-EFFICACY ENHANCING STROKE SELF-MANAGEMENT PROGRAM FOR COMMUNITY-DWELLING STROKE SURVIVORS (SESSMP)</i>	33
<i>TABLE 9 CLINICAL TRIAL: ADAPTIVE PHYSICAL ACTIVITY FOR CHRONIC STROKE</i>	34
<i>TABLE 10 CLINICAL TRIAL: TAILORED APPROACHES TO STROKE HEALTH EDUCATION (TASHE)</i>	36
<i>TABLE 11 CLINICAL TRIAL: PROSPECTIVE STROKE COHORT</i>	37
SUPPLY CHAIN PROCESS AND MARKET ANALYSIS	39
<i>FIGURE 6 SUPPLY CHAIN ANALYSIS - STROKE DIAGNOSIS AND MANAGEMENT</i>	39
<i>FIGURE 7 FACTORS THAT INFLUENCE THE QUALITY OF THE STROKE MANAGEMENT SUPPLY CHAIN</i>	39
GEOGRAPHIC MARKET ANALYSIS: DEVELOPED VERSUS DEVELOPING ECONOMIES	40
<i>TABLE 12 HEALTHCARE EXPENDITURE COMPARISON, DEVELOPED VERSUS DEVELOPING ECONOMIES, 2008-2012* (% OF GDP)</i>	41
REGULATIONS, GOVERNMENT POLICIES, ENVIRONMENT CLEARANCES, CE MARK/FDA APPROVALS ETC	41
GOVERNMENT REGULATIONS - POLICY CHANGES TO IMPROVE STROKE CARE, U.S.	41
NATIONAL SUMMARY OF STATE POLICY AND REGULATION	42
<i>FIGURE 8 TIMELINE FOR ENACTMENT OF PRIMARY STROKE CENTER LEGISLATIVE OR NON-LEGISLATIVE POLICY, JULY 2010</i>	42
Type of Policy	42
CDC FUNDING	43
National Heart Disease and Stroke Prevention Program	43
Paul Coverdell National Acute Stroke Registry	44
Stroke Networks	44
NATIONAL STROKE STRATEGY, U.K.	45
CE MARK/FDA APPROVALS	47
CASE STUDIES AND BRIEF: EMERGING DEVICE-BASED ENDOVASCULAR THERAPIES	48
CEREBRAL EMBOLECTOMY/THROMBECTOMY SYSTEMS- CONCENTRIC MEDICAL	48
MERCİ RETRIEVER	49

TOPIC	PAGE NO.
PATIENT ENROLMENT FOR CLINICAL TRIALS - TREVO 2 IN FEBRUARY, 2011	50
EKOS	50
Aim	50
Methods	50
Results	51
Discussion	51
Conclusion	51
FDA APPROVAL OF BOSTON SCIENTIFIC'S STROKE FIGHTING DEVICE	52
EV3 - COMPARISON OF TWO STROKE DEVICES: APERIO CLOT REMOVAL AND EV3'S - SOLITAIRE AB/FR	52
Background	52
Materials and Methods	52
Results	53
Discussion	53
MICRUS ENDOVASCULAR - EFFECTIVENESS OF MICRUS ENDOVASCULAR PHAROS ON A PATIENT	54
Clinical History	54
Technology Involved	54
Conclusion	54
BRAINSGATE - FDA APPROVAL ON ITS STROKE TREATMENT STUDY	54
BrainsGate Changed Stroke Treatment Pivotal Trial Structure in January, 2013	55
COAXIA	55
The SENTIS Stroke Trial	55
MARKET INTELLIGENCE	56
<i>FIGURE 9 RECENT DEVELOPMENTS BY COMPANY, 2011-2014 (NUMBER OF PROJECTS)</i>	58
MARKET DYNAMICS	59
<i>FIGURE 10 GLOBAL POPULATION GROWTH, BY AGE GROUP, 2010-2020 (MILLIONS)</i>	59
EMERGING ENDOVASCULAR THERAPEUTIC SYSTEMS	60
CEREBRAL EMBOLLECTOMY/THROMBECTOMY SYSTEMS	61
INTRACRANIAL STENTING SYSTEMS	61
CEREBRAL PERFUSION AUGMENTATION SYSTEMS	61
CURRENT SCENARIO AND FUTURE TRENDS	62
ANALYSIS, CONCLUSIONS AND RECOMMENDATIONS	62
CHAPTER 4 STROKE DIAGNOSTIC AND MANAGEMENT DEVICES MARKET	65
STROKE DIAGNOSTICS	65
DIAGNOSTIC IMAGING	66
<i>TABLE 13 GLOBAL STROKE DIAGNOSTIC IMAGING MARKET, THROUGH 2019 (\$ MILLIONS)</i>	66
<i>TABLE 14 GLOBAL STROKE DIAGNOSTIC IMAGING MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	66
Computed Tomography	67
<i>TABLE 15 GLOBAL COMPUTED TOMOGRAPHY MARKET BY SYSTEM, THROUGH 2019 (\$ MILLIONS)</i>	67
<i>TABLE 16 GLOBAL COMPUTED TOMOGRAPHY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	68
Spiral Computed Tomography	68

TOPIC	PAGE NO.
<i>TABLE 17 GLOBAL SPIRAL COMPUTED TOMOGRAPHY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	68
Multislice Computed Tomography	69
<i>TABLE 18 GLOBAL MULTISLICE COMPUTED TOMOGRAPHY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	69
Dual Source Multislice CT	69
<i>TABLE 19 GLOBAL DUAL SOURCE MULTISLICE COMPUTED TOMOGRAPHY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	70
Computed Tomography Angiography	70
<i>TABLE 20 GLOBAL COMPUTED TOMOGRAPHY ANGIOGRAPHY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	70
Perfusion Computed Tomography	71
<i>TABLE 21 GLOBAL PERFUSION COMPUTED TOMOGRAPHY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	71
Magnetic Resonance Imaging	71
<i>TABLE 22 GLOBAL MRI MARKET BY TYPES, THROUGH 2019 (\$ MILLIONS)</i>	72
<i>TABLE 23 GLOBAL MRI MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	72
Magnetic Resonance Angiography	72
<i>TABLE 24 GLOBAL MAGNETIC RESONANCE ANGIOGRAPHY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	73
Time-of-Flight Magnetic Resonance Angiography	73
<i>TABLE 25 GLOBAL TOF-MRA MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	73
Phase-Contrast Magnetic Resonance Angiography	74
<i>TABLE 26 GLOBAL PC-MRA MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	74
Contrast-Enhanced Magnetic Resonance Angiography	74
<i>TABLE 27 GLOBAL CE-MRA MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	75
Functional Magnetic Resonance Imaging	75
<i>TABLE 28 GLOBAL FMRI MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	75
Proton Magnetic Resonance Spectroscopy	75
<i>TABLE 29 GLOBAL PROTON MAGNETIC RESONANCE SPECTROSCOPY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	76
Diagnostic Ultrasound	76
<i>TABLE 30 GLOBAL DIAGNOSTIC ULTRASOUND MARKET, THROUGH 2019 (\$ MILLIONS)</i>	76
<i>TABLE 31 GLOBAL DIAGNOSTIC ULTRASOUND MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	77
Doppler Ultrasound	77
<i>TABLE 32 GLOBAL DOPPLER ULTRASOUND MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	78
Duplex Ultrasound	78
<i>TABLE 33 GLOBAL DUPLEX ULTRASOUND MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	78
Cerebral Angiography	79
<i>TABLE 34 GLOBAL CEREBRAL ANGIOGRAPHY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	79
Nuclear Imaging	79
<i>TABLE 35 GLOBAL NUCLEAR IMAGING MARKET, THROUGH 2019 (\$ MILLIONS)</i>	80
<i>TABLE 36 GLOBAL NUCLEAR IMAGING MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	80
Gamma Camera Imaging	80

TOPIC	PAGE NO.
<i>TABLE 37 GLOBAL GAMMA CAMERA IMAGING MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	81
Positron Emission Tomography	81
<i>TABLE 38 GLOBAL PET MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	81
CHAPTER 5 THERAPEUTIC MANAGEMENT OF STROKE	83
<i>TABLE 39 GLOBAL THERAPEUTIC MANAGEMENT MARKET OF STROKE BY DRUG CATEGORY, THROUGH 2019 (\$ MILLIONS)</i>	84
ANTICOAGULATION THERAPY	84
COUMARINS (VITAMIN K ANTAGONISTS)	84
HEPARIN AND DERIVATIVE SUBSTANCES	85
OTHERS	85
<i>TABLE 40 GLOBAL ANTICOAGULATION THERAPY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	86
ANTIHYPERTENSIVE DRUG THERAPY	86
<i>TABLE 41 GLOBAL ANTIHYPERTENSIVE DRUG THERAPY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	86
ANTIPLATELET DRUG THERAPY	87
<i>TABLE 42 GLOBAL ANTIPLATELET DRUG THERAPY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	87
OTHER DRUG THERAPIES	87
<i>TABLE 43 GLOBAL OTHER DRUG THERAPY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	89
KEY STROKE MANAGEMENT DRUGS (GENERIC) ANALYSIS	89
<i>TABLE 44 GLOBAL STROKE MANAGEMENT DRUG MARKET, THROUGH 2019 (\$ MILLIONS)</i>	90
WARFARIN	90
<i>TABLE 45 GLOBAL WARFARIN MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	91
DABIGATRAN	91
<i>TABLE 46 GLOBAL DABIGATRAN MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	91
NADROPERIN	92
<i>TABLE 47 GLOBAL NADROPERIN MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	92
ENAXOPERIN	92
<i>TABLE 48 GLOBAL ENAXOPERIN MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	92
ATENOLOL	93
<i>TABLE 49 GLOBAL ATENOLOL MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	93
METOPROLOL	93
<i>TABLE 50 GLOBAL METOPROLOL MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	93
PINDOLOL	94
<i>TABLE 51 GLOBAL PINDOLOL MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	94
HYDROCHLOROTHIAZIDE	94
<i>TABLE 52 GLOBAL HYDROCHLOROTHIAZIDE MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	94
LOSARTAN	95
<i>TABLE 53 GLOBAL LOSARTAN MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	95
ENALAPRIL	95
<i>TABLE 54 GLOBAL ENALAPRIL MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	95
LISINOPRIL	96
<i>TABLE 55 GLOBAL LISINOPRIL MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	96

TOPIC	PAGE NO.
FELODIPINE	96
TABLE 56 GLOBAL FELODIPINE MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	96
ASPIRIN	97
TABLE 57 GLOBAL ASPIRIN MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	97
DIPYRIDAMOLE	97
TABLE 58 GLOBAL DIPYRIDAMOLE MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	97
CLOPIDOGREL	98
TABLE 59 GLOBAL CLOPIDOGREL MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	98
ALTEPLASE	98
STROKE-RELATED SURGICAL AND ENDOVASCULAR INTERVENTIONS	98
TABLE 60 GLOBAL STROKE RELATED SURGICAL AND ENDOVASCULAR INTERVENTIONS MARKET, THROUGH 2019 (\$ MILLIONS)	99
TABLE 61 GLOBAL STROKE RELATED SURGICAL AND ENDOVASCULAR INTERVENTIONS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	99
TREATMENT OF STROKE-PRONE CAROTID ARTERY STENOSIS	99
TABLE 62 GLOBAL STROKE-PRONE CAROTID ARTERY STENOSIS MARKET, THROUGH 2019 (\$ MILLIONS)	100
TABLE 63 GLOBAL STROKE-PRONE CAROTID ARTERY STENOSIS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	100
Carotid Endarterectomy	100
TABLE 64 GLOBAL CAROTID ENDARTERECTOMY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	101
Carotid Artery Stenting	101
TABLE 65 GLOBAL CAROTID ARTERY STENTING MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	102
MANAGEMENT OF INTRACRANIAL ANEURYSMS AND ARTERIOVENOUS MALFORMATIONS	102
TABLE 66 GLOBAL INTRACRANIAL ANEURYSMS AND ARTERIOVENOUS MALFORMATIONS MARKET, THROUGH 2019 (\$ MILLIONS)	102
TABLE 67 GLOBAL INTRACRANIAL ANEURYSMS AND ARTERIOVENOUS MALFORMATIONS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	103
Intracranial Aneurysms	103
TABLE 68 GLOBAL INTRACRANIAL ANEURYSMS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	103
Arteriovenous Malformations	104
TABLE 69 GLOBAL ARTERIOVENOUS MALFORMATIONS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	104
Surgical Repair	104
TABLE 70 GLOBAL SURGICAL REPAIR MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	105
Endovascular Embolization	105
TABLE 71 GLOBAL ENDOVASCULAR EMBOLIZATION MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	105
Stereotactic Radiotherapy	105
TABLE 72 GLOBAL STEREOTACTIC RADIOTHERAPY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	106
CHAPTER 6 MARKET BY TYPES OF STROKES	108

TOPIC	PAGE NO.
<i>TABLE 73 GLOBAL STROKES MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)</i>	108
HEMORRHAGIC	108
<i>TABLE 74 GLOBAL HEMORRHAGIC STROKES MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)</i>	109
<i>TABLE 75 GLOBAL HEMORRHAGIC STROKES MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	109
INTRACEREBRAL	109
<i>TABLE 76 GLOBAL INTRACEREBRAL STROKES MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	110
SUBARACHNOID HEMORRHAGE	110
<i>TABLE 77 GLOBAL SUBARACHNOID HEMORRHAGE STROKES MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	111
ISCHEMIC	111
<i>TABLE 78 GLOBAL ISCHEMIC STROKES MARKET, THROUGH 2019 (\$ MILLIONS)</i>	112
<i>TABLE 79 GLOBAL ISCHEMIC STROKES MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	112
THROMBOTIC	112
Unmet Medical Need	112
European Companies are the Major Players	113
<i>TABLE 80 GLOBAL THROMBOTIC STROKES MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	114
EMBOLIC	114
<i>TABLE 81 GLOBAL EMBOLIC STROKES MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	114
TRANSIENT ISCHEMIC ATTACK (TIA)	114
<i>TABLE 82 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	115
CHAPTER 7 STROKE MANAGEMENT MARKET BY STAKEHOLDERS	117
SUPPLY CHAIN MEMBERS	117
<i>TABLE 83 GLOBAL STROKE MANAGEMENT MARKET BY SUPPLY CHAIN MEMBERS, THROUGH 2019 (\$ MILLIONS)</i>	117
MANUFACTURERS	117
<i>TABLE 84 GLOBAL STROKE MANAGEMENT MARKET-MANUFACTURERS, BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	119
DISTRIBUTORS	120
<i>TABLE 85 GLOBAL STROKE MANAGEMENT MARKET-DISTRIBUTORS, BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	120
SUPPLIERS	120
<i>TABLE 86 GLOBAL STROKE MANAGEMENT MARKET-SUPPLIERS, BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	120
END-USERS	121
<i>TABLE 87 GLOBAL STROKE MANAGEMENT MARKET BY END USERS, THROUGH 2019 (\$ MILLIONS)</i>	121
LIFE SCIENCES	121
<i>TABLE 88 GLOBAL STROKE MANAGEMENT MARKET-LIFE SCIENCES, BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	122
HOSPITALS	122
<i>TABLE 89 GLOBAL STROKE MANAGEMENT MARKET-HOSPITALS, BY SIZE, THROUGH 2019 (\$ MILLIONS)</i>	122

TOPIC	PAGE NO.
<i>TABLE 90 GLOBAL STROKE MANAGEMENT MARKET-HOSPITALS, BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	123
DIAGNOSTIC CENTERS	123
<i>TABLE 91 GLOBAL STROKE MANAGEMENT MARKET-DIAGNOSTIC CENTERS, BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	123
PATIENTS	123
<i>TABLE 92 GLOBAL STROKE MANAGEMENT MARKET-PATIENTS, BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	124
CHAPTER 8 COMPETITIVE LANDSCAPE	126
<i>FIGURE 11 RECENT DEVELOPMENT BY STRATEGIES, 2011 TO 2014 (NUMBER)</i>	126
CERTIFICATION	127
<i>FIGURE 12 CERTIFICATION BY COMPANIES, 2011 TO 2014 (NUMBER OF CERTIFICATIONS)</i>	127
<i>TABLE 93 RECENT DEVELOPMENT - CERTIFICATION BY COMPANY, 2011 TO 2014</i>	128
PRODUCT LAUNCH	129
<i>FIGURE 13 PRODUCT LAUNCH BY COMPANIES, 2011 TO 2014 (NUMBER OF LAUNCHES)</i>	130
<i>TABLE 94 RECENT DEVELOPMENT-PRODUCT LAUNCH BY COMPANY, 2011 TO 2014</i>	131
CHAPTER 9 GEOGRAPHIC ANALYSIS	133
NORTH AMERICA	133
<i>TABLE 95 NORTH AMERICAN STROKE MANAGEMENT MARKET, THROUGH 2019 (\$ MILLIONS)</i>	134
EUROPE	134
<i>TABLE 96 EUROPE GERIATRIC POPULATION STATISTICS, 1991 AND 2011 (MILLIONS)</i>	135
<i>TABLE 97 EUROPEAN STROKE MANAGEMENT MARKET, THROUGH 2019 (\$ MILLIONS)</i>	135
ASIA	136
<i>TABLE 98 ASIA GERIATRIC POPULATION STATISTICS, 2000 AND 2025 (MILLIONS)</i>	136
<i>TABLE 99 ASIAN STROKE MANAGEMENT MARKET, THROUGH 2019 (\$ MILLIONS)</i>	137
REST OF THE WORLD	137
<i>TABLE 100 ROW STROKE MANAGEMENT MARKET, THROUGH 2019 (\$ MILLIONS)</i>	138
CHAPTER 10 PATENT ANALYSIS	140
<i>FIGURE 14 GLOBAL PATENTS BY COMPANY, 2008 TO 2014 (NO. OF PATENTS)</i>	140
U.S. PATENT ANALYSIS	141
<i>FIGURE 15 U.S. PATENTS BY TECHNOLOGY, 2008 TO 2014 (NO. OF PATENTS)</i>	141
<i>FIGURE 16 U.S. PATENTS BY COMPANY, 2008 TO 2014 (NO. OF PATENTS)</i>	143
EUROPEAN PATENT ANALYSIS	143
<i>FIGURE 17 EUROPEAN PATENTS BY TECHNOLOGY, 2008 TO 2014 (NO. OF PATENTS)</i>	144
<i>FIGURE 18 EUROPEAN PATENTS BY COMPANY, 2008 TO 2014 (NO. OF PATENTS)</i>	145
JAPAN PATENT ANALYSIS	146
<i>FIGURE 19 JAPAN PATENTS BY TECHNOLOGY, 2008 TO 2014 (NO. OF PATENTS)</i>	146
<i>FIGURE 20 JAPAN PATENTS BY COMPANY, 2008 TO 2014 (NO. OF PATENTS)</i>	146
CHAPTER 11 COMPANY PROFILES	149
ABBOTT VASCULAR	149
<i>TABLE 101 ABBOTT VASCULAR'S PRODUCT PORTFOLIO</i>	149

TOPIC	PAGE NO.
<i>TABLE 102 ABBOTT VASCULAR'S RECENT DEVELOPMENTS, 2011 TO AUG 2014</i>	150
B BRAUN MELSUNGEN AG	150
<i>TABLE 103 B BRAUN'S PRODUCT PORTFOLIO</i>	151
BOSTON SCIENTIFIC CORP.	151
<i>TABLE 104 BOSTON SCIENTIFIC'S PRODUCT PORTFOLIO</i>	152
<i>TABLE 105 BOSTON SCIENTIFIC'S RECENT DEVELOPMENTS, 2011 TO JUNE 2014</i>	152
BRISTOL-MYERS SQUIBB	153
<i>TABLE 106 BRISTOL MYERS SQUIBB PRODUCT PORTFOLIO</i>	154
<i>TABLE 107 BRISTOL MYERS SQUIBB RECENT DEVELOPMENTS - 2011 TO SEP 2014</i>	154
COAXIA INC.	154
<i>TABLE 108 COAXIA INC PRODUCT PORTFOLIO</i>	155
CORDIS CORP.	155
<i>TABLE 109 CORDIS CORP. PRODUCT PORTFOLIO</i>	155
GE HEALTHCARE	156
<i>TABLE 110 GE HEALTHCARE PRODUCT PORTFOLIO</i>	156
<i>TABLE 111 GE HEALTHCARE RECENT DEVELOPMENTS, 2011 TO AUG 2014</i>	157
GENENTECH INC.	157
<i>TABLE 112 GENENTECH'S PRODUCT PORTFOLIO</i>	158
GLAXOSMITHKLINE PLC.	158
<i>TABLE 113 GLAXOSMITHKLINE PLC PRODUCT PORTFOLIO</i>	159
MERCK & COMPANY	159
<i>TABLE 114 MERCK'S PRODUCT PORTFOLIO</i>	159
<i>TABLE 115 MERCK'S RECENT DEVELOPMENTS 2011 TO SEP 2014</i>	160
MIZUHO AMERICA INC.	160
<i>TABLE 116 MIZUHO AMERICA'S PRODUCT PORTFOLIO</i>	160
PHILIPS HEALTHCARE	160
<i>TABLE 117 PHILIPS HEALTHCARE PRODUCT PORTFOLIO</i>	161
<i>TABLE 118 PHILIPS HEALTHCARE RECENT DEVELOPMENTS, 2011 TO APRIL 2014</i>	161
SIEMENS HEALTHCARE	162
<i>TABLE 119 SIEMENS HEALTHCARE'S PRODUCT PORTFOLIO</i>	162
CHAPTER 12 APPENDIX	164
UNITED STATES	164
<i>TABLE 120 U.S. PATENT LIST, 2011 TO 2014</i>	164
EUROPE	168
<i>TABLE 121 EUROPEAN PATENT LIST, 2011 TO 2014</i>	168
JAPAN	172
<i>TABLE 122 JAPAN PATENT LIST, 2011 TO 2014</i>	172

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL STROKE MANAGEMENT MARKET, THROUGH 2019 (\$ MILLIONS)	7
TABLE 1 RISK FACTORS OF STROKE	14
TABLE 2 PREVALENCE OF STROKE IN THE U.K. BY REGION AND GENDER, 2010 (%)	17
TABLE 3 TOTAL NUMBER OF DEATHS FROM STROKE IN THE U.K. BY REGION, 2010 (NUMBER)	18
TABLE 4 ROLE OF BIOMARKERS	25
TABLE 5 BIOMARKERS FOR SPECIFIC STROKE SUBTYPES	27
TABLE 6 ADVANTAGES AND DISADVANTAGES OF BIOMARKERS BY TYPE	30
TABLE 7 POST STROKE DISEASE MANAGEMENT - CLINICAL TRIAL	30
TABLE 8 CLINICAL TRIAL: A SELF-EFFICACY ENHANCING STROKE SELF-MANAGEMENT PROGRAM FOR COMMUNITY-DWELLING STROKE SURVIVORS (SESSMP)	33
TABLE 9 CLINICAL TRIAL: ADAPTIVE PHYSICAL ACTIVITY FOR CHRONIC STROKE	34
TABLE 10 CLINICAL TRIAL: TAILORED APPROACHES TO STROKE HEALTH EDUCATION (TASHE)	36
TABLE 11 CLINICAL TRIAL: PROSPECTIVE STROKE COHORT	37
TABLE 12 HEALTHCARE EXPENDITURE COMPARISON, DEVELOPED VERSUS DEVELOPING ECONOMIES, 2008-2012* (% OF GDP)	41
TABLE 13 GLOBAL STROKE DIAGNOSTIC IMAGING MARKET, THROUGH 2019 (\$ MILLIONS)	66
TABLE 14 GLOBAL STROKE DIAGNOSTIC IMAGING MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	66
TABLE 15 GLOBAL COMPUTED TOMOGRAPHY MARKET BY SYSTEM, THROUGH 2019 (\$ MILLIONS)	67
TABLE 16 GLOBAL COMPUTED TOMOGRAPHY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	68
TABLE 17 GLOBAL SPIRAL COMPUTED TOMOGRAPHY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	68
TABLE 18 GLOBAL MULTISLICE COMPUTED TOMOGRAPHY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	69
TABLE 19 GLOBAL DUAL SOURCE MULTISLICE COMPUTED TOMOGRAPHY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	70
TABLE 20 GLOBAL COMPUTED TOMOGRAPHY ANGIOGRAPHY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	70
TABLE 21 GLOBAL PERFUSION COMPUTED TOMOGRAPHY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	71
TABLE 22 GLOBAL MRI MARKET BY TYPES, THROUGH 2019 (\$ MILLIONS)	72
TABLE 23 GLOBAL MRI MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	72
TABLE 24 GLOBAL MAGNETIC RESONANCE ANGIOGRAPHY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	73
TABLE 25 GLOBAL TOF-MRA MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	73
TABLE 26 GLOBAL PC-MRA MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	74
TABLE 27 GLOBAL CE-MRA MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	75
TABLE 28 GLOBAL FMRI MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	75
TABLE 29 GLOBAL PROTON MAGNETIC RESONANCE SPECTROSCOPY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	76
TABLE 30 GLOBAL DIAGNOSTIC ULTRASOUND MARKET, THROUGH 2019 (\$ MILLIONS)	76
TABLE 31 GLOBAL DIAGNOSTIC ULTRASOUND MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	77

TABLE HEADING	PAGE NO.
TABLE 32 GLOBAL DOPPLER ULTRASOUND MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	78
TABLE 33 GLOBAL DUPLEX ULTRASOUND MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	78
TABLE 34 GLOBAL CEREBRAL ANGIOGRAPHY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	79
TABLE 35 GLOBAL NUCLEAR IMAGING MARKET, THROUGH 2019 (\$ MILLIONS)	80
TABLE 36 GLOBAL NUCLEAR IMAGING MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	80
TABLE 37 GLOBAL GAMMA CAMERA IMAGING MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	81
TABLE 38 GLOBAL PET MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	81
TABLE 39 GLOBAL THERAPEUTIC MANAGEMENT MARKET OF STROKE BY DRUG CATEGORY, THROUGH 2019 (\$ MILLIONS)	84
TABLE 40 GLOBAL ANTICOAGULATION THERAPY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	86
TABLE 41 GLOBAL ANTIHYPERTENSIVE DRUG THERAPY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	86
TABLE 42 GLOBAL ANTIPLATELET DRUG THERAPY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	87
TABLE 43 GLOBAL OTHER DRUG THERAPY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	89
TABLE 44 GLOBAL STROKE MANAGEMENT DRUG MARKET, THROUGH 2019 (\$ MILLIONS)	90
TABLE 45 GLOBAL WARFARIN MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	91
TABLE 46 GLOBAL DABIGATRAN MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	91
TABLE 47 GLOBAL NADROPERIN MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	92
TABLE 48 GLOBAL ENAXOPERIN MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	92
TABLE 49 GLOBAL ATENOLOL MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	93
TABLE 50 GLOBAL METOPROLOL MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	93
TABLE 51 GLOBAL PINDOLOL MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	94
TABLE 52 GLOBAL HYDROCHLOROTHIAZIDE MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	94
TABLE 53 GLOBAL LOSARTAN MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	95
TABLE 54 GLOBAL ENALAPRIL MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	95
TABLE 55 GLOBAL LISINOPRIL MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	96
TABLE 56 GLOBAL FELODIPINE MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	96
TABLE 57 GLOBAL ASPIRIN MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	97
TABLE 58 GLOBAL DIPYRIDAMOLE MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	97
TABLE 59 GLOBAL CLOPIDOGREL MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	98
TABLE 60 GLOBAL STROKE RELATED SURGICAL AND ENDOVASCULAR INTERVENTIONS MARKET, THROUGH 2019 (\$ MILLIONS)	99
TABLE 61 GLOBAL STROKE RELATED SURGICAL AND ENDOVASCULAR INTERVENTIONS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	99
TABLE 62 GLOBAL STROKE-PRONE CAROTID ARTERY STENOSIS MARKET, THROUGH 2019 (\$ MILLIONS)	100
TABLE 63 GLOBAL STROKE-PRONE CAROTID ARTERY STENOSIS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	100
TABLE 64 GLOBAL CAROTID ENDARTERECTOMY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	101

TABLE HEADING	PAGE NO.
TABLE 65 GLOBAL CAROTID ARTERY STENTING MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	102
TABLE 66 GLOBAL INTRACRANIAL ANEURYSMS AND ARTERIOVENOUS MALFORMATIONS MARKET, THROUGH 2019 (\$ MILLIONS)	102
TABLE 67 GLOBAL INTRACRANIAL ANEURYSMS AND ARTERIOVENOUS MALFORMATIONS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	103
TABLE 68 GLOBAL INTRACRANIAL ANEURYSMS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	103
TABLE 69 GLOBAL ARTERIOVENOUS MALFORMATIONS MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	104
TABLE 70 GLOBAL SURGICAL REPAIR MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	105
TABLE 71 GLOBAL ENDOVASCULAR EMBOLIZATION MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	105
TABLE 72 GLOBAL STEREOTACTIC RADIOTHERAPY MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	106
TABLE 73 GLOBAL STROKES MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)	108
TABLE 74 GLOBAL HEMORRHAGIC STROKES MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)	109
TABLE 75 GLOBAL HEMORRHAGIC STROKES MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	109
TABLE 76 GLOBAL INTRACEREBRAL STROKES MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	110
TABLE 77 GLOBAL SUBARACHNOID HEMORRHAGE STROKES MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	111
TABLE 78 GLOBAL ISCHEMIC STROKES MARKET, THROUGH 2019 (\$ MILLIONS)	112
TABLE 79 GLOBAL ISCHEMIC STROKES MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	112
TABLE 80 GLOBAL THROMBOTIC STROKES MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	114
TABLE 81 GLOBAL EMBOLIC STROKES MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	114
TABLE 82 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	115
TABLE 83 GLOBAL STROKE MANAGEMENT MARKET BY SUPPLY CHAIN MEMBERS, THROUGH 2019 (\$ MILLIONS)	117
TABLE 84 GLOBAL STROKE MANAGEMENT MARKET-MANUFACTURERS, BY REGION, THROUGH 2019 (\$ MILLIONS)	119
TABLE 85 GLOBAL STROKE MANAGEMENT MARKET-DISTRIBUTORS, BY REGION, THROUGH 2019 (\$ MILLIONS)	120
TABLE 86 GLOBAL STROKE MANAGEMENT MARKET-SUPPLIERS, BY REGION, THROUGH 2019 (\$ MILLIONS)	120
TABLE 87 GLOBAL STROKE MANAGEMENT MARKET BY END USERS, THROUGH 2019 (\$ MILLIONS)	121
TABLE 88 GLOBAL STROKE MANAGEMENT MARKET-LIFE SCIENCES, BY REGION, THROUGH 2019 (\$ MILLIONS)	122
TABLE 89 GLOBAL STROKE MANAGEMENT MARKET-HOSPITALS, BY SIZE, THROUGH 2019 (\$ MILLIONS)	122
TABLE 90 GLOBAL STROKE MANAGEMENT MARKET-HOSPITALS, BY REGION, THROUGH 2019 (\$ MILLIONS)	123
TABLE 91 GLOBAL STROKE MANAGEMENT MARKET-DIAGNOSTIC CENTERS, BY REGION, THROUGH 2019 (\$ MILLIONS)	123

TABLE HEADING	PAGE NO.
TABLE 92 GLOBAL STROKE MANAGEMENT MARKET-PATIENTS, BY REGION, THROUGH 2019 (\$ MILLIONS)	124
TABLE 93 RECENT DEVELOPMENT - CERTIFICATION BY COMPANY, 2011 TO 2014	128
TABLE 94 RECENT DEVELOPMENT-PRODUCT LAUNCH BY COMPANY, 2011 TO 2014	131
TABLE 95 NORTH AMERICAN STROKE MANAGEMENT MARKET, THROUGH 2019 (\$ MILLIONS)	134
TABLE 96 EUROPE GERIATRIC POPULATION STATISTICS, 1991 AND 2011 (MILLIONS)	135
TABLE 97 EUROPEAN STROKE MANAGEMENT MARKET, THROUGH 2019 (\$ MILLIONS)	135
TABLE 98 ASIA GERIATRIC POPULATION STATISTICS, 2000 AND 2025 (MILLIONS)	136
TABLE 99 ASIAN STROKE MANAGEMENT MARKET, THROUGH 2019 (\$ MILLIONS)	137
TABLE 100 ROW STROKE MANAGEMENT MARKET, THROUGH 2019 (\$ MILLIONS)	138
TABLE 101 ABBOTT VASCULAR'S PRODUCT PORTFOLIO	149
TABLE 102 ABBOTT VASCULAR'S RECENT DEVELOPMENTS, 2011 TO AUG 2014	150
TABLE 103 B BRAUN'S PRODUCT PORTFOLIO	151
TABLE 104 BOSTON SCIENTIFIC'S PRODUCT PORTFOLIO	152
TABLE 105 BOSTON SCIENTIFIC'S RECENT DEVELOPMENTS, 2011 TO JUNE 2014	152
TABLE 106 BRISTOL MYERS SQUIBB PRODUCT PORTFOLIO	154
TABLE 107 BRISTOL MYERS SQUIBB RECENT DEVELOPMENTS - 2011 TO SEP 2014	154
TABLE 108 COAXIA INC PRODUCT PORTFOLIO	155
TABLE 109 CORDIS CORP. PRODUCT PORTFOLIO	155
TABLE 110 GE HEALTHCARE PRODUCT PORTFOLIO	156
TABLE 111 GE HEALTHCARE RECENT DEVELOPMENTS, 2011 TO AUG 2014	157
TABLE 112 GENENTECH'S PRODUCT PORTFOLIO	158
TABLE 113 GLAXOSMITHKLINE PLC PRODUCT PORTFOLIO	159
TABLE 114 MERCK'S PRODUCT PORTFOLIO	159
TABLE 115 MERCK'S RECENT DEVELOPMENTS 2011 TO SEP 2014	160
TABLE 116 MIZUHO AMERICA'S PRODUCT PORTFOLIO	160
TABLE 117 PHILIPS HEALTHCARE PRODUCT PORTFOLIO	161
TABLE 118 PHILIPS HEALTHCARE RECENT DEVELOPMENTS, 2011 TO APRIL 2014	161
TABLE 119 SIEMENS HEALTHCARE'S PRODUCT PORTFOLIO	162
TABLE 120 U.S. PATENT LIST, 2011 TO 2014	164
TABLE 121 EUROPEAN PATENT LIST, 2011 TO 2014	168
TABLE 122 JAPAN PATENT LIST, 2011 TO 2014	172

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL STROKE MANAGEMENT MARKET, 2013-2019 (\$ MILLIONS)	7
FIGURE 1 TOP 10 LEADING CAUSES OF DEATH IN THE WORLD, 2012 (MILLIONS)	13
FIGURE 2 NUMBER OF STROKES IN THE WORLD, 1990-2010 (MILLIONS)	15
FIGURE 3 GLOBAL INCIDENCE AND PREVALENCE OF STROKE BY REGION, 2010 (%)	16
FIGURE 4 U.S. PREVALENCE OF STROKE BY AGE AND GENDER IN PERCENTAGE OF POPULATION, 2010 (%)	18
FIGURE 5 ALGORITHM FOR THE DIAGNOSIS OF ACUTE STROKE	19
FIGURE 6 SUPPLY CHAIN ANALYSIS - STROKE DIAGNOSIS AND MANAGEMENT	39
FIGURE 7 FACTORS THAT INFLUENCE THE QUALITY OF THE STROKE MANAGEMENT SUPPLY CHAIN	39
FIGURE 8 TIMELINE FOR ENACTMENT OF PRIMARY STROKE CENTER LEGISLATIVE OR NON-LEGISLATIVE POLICY, JULY 2010	42
FIGURE 9 RECENT DEVELOPMENTS BY COMPANY, 2011-2014 (NUMBER OF PROJECTS)	58
FIGURE 10 GLOBAL POPULATION GROWTH, BY AGE GROUP, 2010-2020 (MILLIONS)	59
FIGURE 11 RECENT DEVELOPMENT BY STRATEGIES, 2011 TO 2014 (NUMBER)	126
FIGURE 12 CERTIFICATION BY COMPANIES, 2011 TO 2014 (NUMBER OF CERTIFICATIONS)	127
FIGURE 13 PRODUCT LAUNCH BY COMPANIES, 2011 TO 2014 (NUMBER OF LAUNCHES)	130
FIGURE 14 GLOBAL PATENTS BY COMPANY, 2008 TO 2014 (NO. OF PATENTS)	140
FIGURE 15 U.S. PATENTS BY TECHNOLOGY, 2008 TO 2014 (NO. OF PATENTS)	141
FIGURE 16 U.S. PATENTS BY COMPANY, 2008 TO 2014 (NO. OF PATENTS)	143
FIGURE 17 EUROPEAN PATENTS BY TECHNOLOGY, 2008 TO 2014 (NO. OF PATENTS)	144
FIGURE 18 EUROPEAN PATENTS BY COMPANY, 2008 TO 2014 (NO. OF PATENTS)	145
FIGURE 19 JAPAN PATENTS BY TECHNOLOGY, 2008 TO 2014 (NO. OF PATENTS)	146
FIGURE 20 JAPAN PATENTS BY COMPANY, 2008 TO 2014 (NO. OF PATENTS)	146